Ablitech to begin testing cancer treatment
HATTIESBURG — Ablitech’s CEO Ken Malone announced that the company is closer to advancing technology that has the ability to stop bladder cancer through its product Versadel.
Malone said, “The proof is in the lab; a place where we are seeing very promising ways of ending certain cancers and degenerative diseases as we know them today.”
“Our technology effectively carries the DNA to the cells and releases it, enabling the cells to function like they were always meant to,” chief science officer of Ablitech Dr. Lisa Kemp said.
Ablitech, which received a second round of funding under the Mississippi Seed Fund earlier this month, said it would next begin agenda–testing Versadel in animal models.
Kemp said, “At this point we are limited to what we can do in the lab working with cells to prove that our science works. It is imperative to move our product to the living system to see our theories in action.”
Ablitech is collaborating with professors and Tulane Cancer Center who have an established animal model. Until the models begin, they continue to focus their efforts on purification and optimization in preparation of the study.
To sign up for Mississippi Business Daily Updates, click here.
Twang & Tourism: The Country Music Trail
Still planning that summer vacation?
FOLLOW THE MBJ ON TWITTERMy Tweets
Top Posts & Pages
- Study: Mississippi has highest sales tax rate in U.S.
- Panther Creek megasite — Putting a value proposition out there
- Mississippi State makes NSF ranking of research universities
- TVA president/CEO Johnson tours Techumseh, Yokohama plants
- Chris McDaniel responds to radio show audio clip
- BBB issues warning involving asphalt paving scam
- Tallahatchie General’s listing on auditor’s ‘watchline’ an image set back, CEO says
- Prescription for success — Transcript Pharmacy continues fast growth
- Ex-city worker arrested on false pretense charge
- Panther Creek's location in medical industry zone boosts bio-med prospects